Current Science

Open Access Open Access  Restricted Access Subscription Access

Size Matters:Nanoparticles in Cancer Therapy


Affiliations
1 Pediatric Biology Center, Translational Health Science and Technology Institute, NCR Biotech Cluster, Faridabad 121 001, India
2 Department of Biochemistry, Aligarh Muslim University, Aligarh 202 002, India
 

The CEO of the corporate giant Apple, Steve Jobs, passed away at the early age of 56 due to a rare form of pancreatic cancer. He was a billionaire who could afford the best of treatment and care. Yet he lost his life to cancer. This is not because there are not enough effective drugs to treat cancer or cancer cells are drug-resistant. It is because the methods of drug delivery are ineffective. Cancer treatment requires a different approach.
User
Notifications
Font Size

  • Harmon, K., The puzzle of pancreatic cancer: how Steve jobs did not beat the odds – but Nobel Winner Ralph Steinman did, 2011; https://www.scientificamerican.com/article/pancreatic-cancer-type-jobs/ (retrieved on 3 November 2016).

  • World Health Organisation, Cancer, 2015; http://www.who.int/mediacentre/factsheets/fs297/en/ (retrieved on 3 November 2016).

  • Eram, S. et al., Spectrochim. Acta Part A, 2016, 168, 123–131.

  • Nguyen, K. T., J. Nanomedic Nanotechnol., 2011, 2(5), 1000103e.

  • Pramanik, A. et al., Mater. Sci. Eng. C, 2016; 68, 327–337

  • Bajwa, N. et al., Artif. Cells Nanomed Biotechnol., 2016, 44(7), 1774–1782.

  • Singh, J. et al., Artif. Cells Nanomed Biotechnol., 2016, 44(7), 1626–1634.


Abstract Views: 279

PDF Views: 73




  • Size Matters:Nanoparticles in Cancer Therapy

Abstract Views: 279  |  PDF Views: 73

Authors

Bhavya Khullar
Pediatric Biology Center, Translational Health Science and Technology Institute, NCR Biotech Cluster, Faridabad 121 001, India
Sarah Iqbal
Department of Biochemistry, Aligarh Muslim University, Aligarh 202 002, India

Abstract


The CEO of the corporate giant Apple, Steve Jobs, passed away at the early age of 56 due to a rare form of pancreatic cancer. He was a billionaire who could afford the best of treatment and care. Yet he lost his life to cancer. This is not because there are not enough effective drugs to treat cancer or cancer cells are drug-resistant. It is because the methods of drug delivery are ineffective. Cancer treatment requires a different approach.

References





DOI: https://doi.org/10.18520/cs%2Fv111%2Fi10%2F1583-1584